Skip to content
Clinical Trials – home

Neurologia Slaska Centrum Medyczne

Verified siteinfo

Poland ul. Małachowskiego 51, 40-689 Katowice, Poland

  • 15 trials recruiting
  • Myasthenia gravis · Chronic inflammatory demyelinating polyradiculoneuropathy · Tourette's disorder
  • Adults and children

About Specializations

Neurologia Slaska Centrum Medyczne in Katowice, Poland specialises in clinical trials of conditions such as Myasthenia gravis, Chronic inflammatory demyelinating polyradiculoneuropathy, Tourette's disorder, Migraine, and other specialisations. This site conducts important research.

Main research areas of the site

Immune System Diseases at Neurologia Slaska Centrum Medyczne

Clinical research here is strongly focused on immune system diseases, especially generalized myasthenia gravis and related antibody-positive and antibody-negative forms. These studies are designed to test new therapies, compare treatment options, and better understand long-term safety and symptom control.

  • Studies in generalized myasthenia gravis are evaluating whether new treatments can improve daily functioning and reduce disease burden.
  • Research also includes ocular myasthenia gravis and pediatric cases, broadening care across age groups and disease subtypes.
  • Several trials assess the safety and effectiveness of emerging immune-targeted therapies compared with placebo or established treatment approaches.
  • Additional work looks at chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, with a focus on maintaining response and improving mobility.

Overall, this site is a notable center for advancing treatment options in antibody-mediated neuromuscular conditions and other immune-related disorders.

Nervous System Diseases Research

The site also supports a broad portfolio in nervous system diseases, with trials spanning movement disorders, dementias, and neurodevelopmental conditions. The main goal is to explore better ways to slow progression, ease symptoms, and improve quality of life.

  • Parkinson disease studies are examining whether new therapies can improve motor fluctuations and reduce time spent “off” medication benefit.
  • Research in multiple sclerosis, including relapsing forms, aims to lower relapse risk and support long-term disease control.
  • Trials in progressive supranuclear palsy, multiple system atrophy, and Alzheimer’s disease are focused on slowing clinical decline and testing novel treatment strategies.
  • Tourette syndrome studies are evaluating medicines intended to help manage tic severity across children, adolescents, and adults.

These studies reflect a strong neurology research environment in Katowice, with attention to both common and rare brain disorders.

Musculoskeletal Diseases and Related Neuromuscular Care

Within musculoskeletal diseases, the research emphasis overlaps with neuromuscular function and disability caused by chronic inflammatory conditions. The trials are mainly aimed at improving strength, preserving function, and evaluating how well treatments work in everyday life.

  • Studies in chronic inflammatory demyelinating polyneuropathy are assessing whether new approaches can help maintain clinical response and support nerve-related function.
  • Research in multifocal motor neuropathy is looking at treatment effectiveness and tolerability in people with weakness and motor impairment.
  • Several projects compare emerging therapies with established immunoglobulin-based care to determine whether outcomes can be improved.
  • The overall focus is on better symptom control, longer-lasting benefit, and more practical treatment options for patients.

At Neurologia Slaska Centrum Medyczne, this area complements the broader neurology portfolio by addressing disorders that affect movement and physical independence.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
ul. Małachowskiego 5140-689 KatowicePoland
Recruiting now
15 trials
Conditions studied
8
Partner status
Verified site

More sites in KatowicePoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

31 clinical trials

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

A Phase 2a Study of Empasiprubart IV Monotherapy in Adults with AChR‑Ab Seropositive Generalized Myasthenia Gravis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

AUR200 for Patients with Generalized Myasthenia Gravis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AUR200

A study to evaluate the safety and effectiveness of empasiprubart and efgartigimod alfa in patients with generalized myasthenia gravis.

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

A study of IM-101 in adults with generalized myasthenia gravis or ocular myasthenia gravis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:IM-101
  • Sponsor:Immunabs Inc.

A study to test if empasiprubart can improve function and is safe for adults with chronic inflammatory demyelinating polyneuropathy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

A Study of IMVT-1402 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy to Prevent Disease Relapse

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Study of IMVT-1402 in Adults with Mild to Severe Generalized Myasthenia Gravis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Migraine

Recruiting

Study on Rimegepant for Preventing Migraines in Children and Teens Aged 6 to 17

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Study on the Long-term Safety of Efgartigimod for Children with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on the Safety and Effectiveness of NMD670 for Adults with Myasthenia Gravis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:NMD670
  • Sponsor:NMD Pharma A/S

Study on Efgartigimod for Children Aged 2-17 with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.